New test may predict who benefits from lung cancer combo therapy
NCT ID NCT04589013
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 25 times
Summary
This study looked at whether a test using 6 different markers from tumor samples could predict if advanced lung cancer patients would live longer or have their cancer worsen after treatment with immunotherapy plus chemotherapy. Researchers studied 106 patients and compared the test's accuracy to the standard PD-L1 test. The goal was to better identify who might benefit from this combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Victor Provot
Roubaix, France
-
Clcc Oscar Lambret Lille
Lille, 59037, France
-
Clinique Teissier
Valenciennes, France
-
Hop Calmette Chu Lille
Lille, 59037, France
Conditions
Explore the condition pages connected to this study.